Biogen moves to dismiss US Walgreen, Kroger's US antitrust claims over Tecfidera
( December 2, 2025, 23:31 GMT | Official Statement) -- MLex Summary: Biogen moved to dismiss US antitrust claims filed by Walgreen Co. and The Kroger Co. accusing it of illegally blocking competition from generic versions of its brand-name drug Tecfidera, saying the amended complaint fails to fix flaws identified by the court. Biogen said the pharmacies lack standing because they are indirect purchasers, seeking to recover for alleged overcharges for branded purchases, in their own names and as assignees of two wholesalers that allegedly purchased branded Tecfidera from Biogen.See attached file....
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.